Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Chromosome 12 open reading frame 57 (C12orf57) encodes a ubiquitously expressed, cytoplasmic protein of 126 amino acids that is especially required in the brain for development of the corpus callosum[1][5][6][7]. Pathogenic variants in C12orf57 are causative for Temtamy syndrome, a rare autosomal recessive disorder characterized by severe developmental delay, epilepsy, variable craniofacial and ocular anomalies (such as colobomatous microphthalmia), and abnormalities of the corpus callosum[4][5]. The precise biochemical function remains unknown, but loss-of-function mutations result in disease due to deficits in neural development, particularly the corpus callosum[1][5]. The gene does not belong to classical receptor, enzyme, or transporter families and has no currently established direct drug interactions or biomarker applications[1][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Chromosome 12 open reading frame 57 (C12orf57).